Log in | Register

Financial conflicts of interest in clinical research

Jelena Savović| Elie A. Akl| Asbjørn Hróbjartsson
Editorial
Volume 44, Issue 10 / October , 2018

Pages 1767 - 1769

No abstract available.

References

  1. Riechelmann RP, Wang L, O’Carroll A, Krzyzanowska MK (2007) Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 25(29):4642–4647
    • View reference on publisher's website
  2. Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS (2011) Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst 103(20):1507–1512
    • View reference on publisher's website
    • View reference on PubMed
  3. Le Noury J, Nardo JM, Healy D et al (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 351(7):h4320
    • View reference on publisher's website
    • View reference on PubMed
  4. Wojcik J (2012) Pharma giant threatens Danish scientist. Science nordic. http://sciencenordic.com/pharma-giant-threatens-danish-scientist. Accessed 15 June 2018
  5. Lo B, Field MJ (eds) (2009) Conflict of interest in medical research, education, and practice. Institute of Medicine (US) Committee on conflict of interest in medical research, education, and practice. National Academies Press (US), Washington (DC)
  6. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:MR000033
    • View reference on PubMed
  7. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL (2003) Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290(7):921–928
    • View reference on publisher's website
    • View reference on PubMed
  8. Hansen C, Lundh A, Rasmussen K, Frandsen TF, Gøtzsche PC, Hróbjartsson A. (2017) The influence of industry funding and other financial conflicts of interest on the outcomes and quality of systematic reviews. In: Eighth international congress on peer review and Scientific Publication Chicago, Illinois, USA, 10–12 Sept 2017
  9. Mann H, Djulbegovic B (2013) Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med 106(1):30–33
    • View reference on publisher's website
    • View reference on PubMed
  10. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260
    • View reference on publisher's website
    • View reference on PubMed
  11. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361(20):1963–1971
    • View reference on publisher's website
    • View reference on PubMed
  12. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064
    • View reference on publisher's website
    • View reference on PubMed
  13. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E, Boscardin WJ, Keyhani S (2017) Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 356:i6770
    • View reference on publisher's website
    • View reference on PubMed
  14. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM (2006) Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 295(16):1921–1928
    • View reference on publisher's website
    • View reference on PubMed
  15. Okike K, Kocher MS, Wei EX, Bhandari M (2009) Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 361(15):1466–1474
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement